Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer
R Pirker - Current opinion in oncology, 2020 - journals.lww.com
Chemotherapy remains a cornerstone in the treatment of nonsm... : Current Opinion in
Oncology Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer …
Oncology Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer …
[HTML][HTML] Conquering lung cancer: current status and prospects for the future
R Pirker - Pulmonology, 2020 - Elsevier
Lung cancer is a major global health problem. Several strategies are required to conquer
this cancer. Stricter implementations of tobacco control measures are necessary. Early …
this cancer. Stricter implementations of tobacco control measures are necessary. Early …
Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small-cell lung cancer: a phase 3 randomized clinical trial
J Wang, S Lu, X Yu, Y Hu, Y Sun, Z Wang… - JAMA …, 2021 - jamanetwork.com
Importance This study demonstrates that tislelizumab in combination with chemotherapy is
associated with improved progression-free survival (PFS) in patients with advanced …
associated with improved progression-free survival (PFS) in patients with advanced …
Nanophotonic immunoarray with electrochemically roughened surfaces for handheld detection of secreted PD-L1 to predict immuno-oncology efficacy
The analysis of secreted protein biomarkers can be a useful non-invasive method of
predicting or monitoring cancer therapeutic response. The increased level of soluble …
predicting or monitoring cancer therapeutic response. The increased level of soluble …
[HTML][HTML] Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient
In recent years, the evolution of treatments has made it possible to significantly improve the
outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular …
outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular …
[HTML][HTML] Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of …
R Kleef, R Nagy, A Baierl, V Bacher, H Bojar… - Cancer Immunology …, 2021 - Springer
The 3-year overall survival (OS) rate of patients with previously treated or untreated stage III
or IV melanoma has by now reached 63% using ipilimumab and nivolumab therapy …
or IV melanoma has by now reached 63% using ipilimumab and nivolumab therapy …
Amplifying outcomes: checkpoint inhibitor combinations in first‐line non‐small cell lung cancer
B Melosky, R Juergens, V Hirsh, D McLeod… - The …, 2020 - academic.oup.com
Purpose Lung cancer is one of the most common types of cancer, resulting in approximately
1.8 million deaths worldwide. Immunotherapy using checkpoint inhibitors has become …
1.8 million deaths worldwide. Immunotherapy using checkpoint inhibitors has become …
[HTML][HTML] Exploring the potential use of a PBMC-based functional assay to identify predictive biomarkers for anti-PD-1 immunotherapy
SM Bacot, TA Harper, RL Matthews, CJ Fennell… - International Journal of …, 2020 - mdpi.com
The absence of reliable, robust, and non-invasive biomarkers for anti-Programmed cell
death protein 1 (PD-1) immunotherapy is an urgent unmet medical need for the treatment of …
death protein 1 (PD-1) immunotherapy is an urgent unmet medical need for the treatment of …
[HTML][HTML] Beyond single-cell analysis of metallodrugs by ICP-MS: targeting cellular substructures
A Galé, L Hofmann, N Lüdi, MN Hungerbühler… - International journal of …, 2021 - mdpi.com
Platinum compounds such as cisplatin (cisPt) embody the backbone of combination
chemotherapy protocols against advanced lung cancer. However, their efficacy is primarily …
chemotherapy protocols against advanced lung cancer. However, their efficacy is primarily …
[HTML][HTML] Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
JH Chung, JS Ha, J Choi, SM Kwon… - Translational Cancer …, 2022 - ncbi.nlm.nih.gov
Background To identify immunotherapy biomarkers, we examined granzyme B levels in
peripheral blood PD-1+ CD8+ T cells and their relationship with treatment outcomes in …
peripheral blood PD-1+ CD8+ T cells and their relationship with treatment outcomes in …